Drug intelligence / Profile preview

SS0515

Development stage: Preclinical
Lead developer: Seedsupply
Modality: Small Molecules

Overview

**SS0515** is a discovery-stage small molecule program from Seedsupply being developed for cancer. The program targets voltage-dependent anion channel 1, a mitochondrial outer membrane protein implicated in apoptosis, cellular stress responses, and tumor cell metabolism. Based on the company pipeline description, SS0515 is intended as a first-in-class VDAC1-modulating anticancer therapy discovered using Seedsupply's Binding Selection Technology platform.

Targets

VDAC1 (Hexokinase 2–voltage-dependent anion channel 1 complex)

Beyond the preview

Go deeper on SS0515.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SS0515.

Explore the full profile